- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma ; volume:18 ; number:1 ; day:22 ; month:6 ; year:2020 ; pages:1-16 ; date:12.2020
BMC medicine ; 18, Heft 1 (22.6.2020), 1-16, 12.2020
- Urheber
-
García-Romero, N.
Palacín-Aliana, I.
Madurga, R.
Carrión-Navarro, J.
Esteban-Rubio, S.
Jiménez, B.
Collazo, A.
Pérez-Rodríguez, F.
Ortiz de Mendivil, A.
Fernández-Carballal, C.
García-Duque, S.
Diamantopoulos-Fernández, J.
Belda-Iniesta, C.
Prat-Acín, R.
Sánchez-Gómez, P.
Calvo, E.
Ayuso-Sacido, A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-020-01610-0
- URN
-
urn:nbn:de:101:1-2020072023003428499282
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- García-Romero, N.
- Palacín-Aliana, I.
- Madurga, R.
- Carrión-Navarro, J.
- Esteban-Rubio, S.
- Jiménez, B.
- Collazo, A.
- Pérez-Rodríguez, F.
- Ortiz de Mendivil, A.
- Fernández-Carballal, C.
- García-Duque, S.
- Diamantopoulos-Fernández, J.
- Belda-Iniesta, C.
- Prat-Acín, R.
- Sánchez-Gómez, P.
- Calvo, E.
- Ayuso-Sacido, A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival